Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 6,768 matching trials from the live ClinicalTrials.gov search.
Filters: Bethesda, Maryland Clear all
Completed No phase listed Observational Accepts healthy volunteers

Effects of Tryptophan Depletion on Brain Processing of Emotions in Patients With Mood Disorders

NCT00097175
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 50 Years
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2019 · Synced Oct 29, 2026, 3:35 PM EDT
Recruiting Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

NCT04339777
View directory record Official record
Conditions
Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
Interventions
Busulfan test dose, Fludarabine, Busulfan, Alemtuzumab, Total body Irradiation, Allogeneic HSCT, Tacrolimus (Tacro), Mycophenolate mofetil (MMF), Cyclophosphamide (Cytoxan)
Drug · Radiation · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
4 Years to 69 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Recurrent Non-Hodgkin's Lymphoma

NCT00004101
View directory record Official record
Conditions
Lymphoma
Interventions
apolizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Iowa City, Iowa • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Drug Interactions of Echinacea, Ginseng, and Ginkgo Biloba Taken With Lopinavir/Ritonavir in Healthy Volunteers

NCT00103012
View directory record Official record
Conditions
Healthy
Interventions
Gingko Biloba, Echinacea purpurea, Panax ginseng
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Oct 29, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional Results available

Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer

NCT02504892
View directory record Official record
Conditions
Renal Cancer, Birt-Hogg-Dube Syndrome
Interventions
Everolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 22, 2019 · Synced Oct 29, 2026, 3:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia

NCT03971799
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
CD33CART autologous, CD33CART allogeneic
Biological
Lead sponsor
Center for International Blood and Marrow Transplant Research
Network
Eligibility
1 Year to 35 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2039
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Antidepressant Effects on cAMP Specific Phosphodiesterase (PDE4) in Depressed Patients

NCT00369798
View directory record Official record
Conditions
Major Depressive Disorder, Healthy
Interventions
PET scan, Rolipram
Procedure · Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 29, 2026, 3:35 PM EDT
Active, not recruiting Phase 2 Interventional

Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma

NCT03919071
View directory record Official record
Conditions
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma, Glioblastoma, Malignant Glioma, WHO Grade 3 Glioma, WHO Grade 4 Glioma
Interventions
Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture, Magnetic Resonance Imaging, Radiation Therapy, Trametinib Dimethyl Sulfoxide
Procedure · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
3 Years to 25 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
130
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 106 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Pilot Study of Thalidomide to Treat Sjogren's Syndrome

NCT00001599
View directory record Official record
Conditions
Sjogren's Syndrome, Xerostomia
Interventions
Thalidomide
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT01836029
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
VTX-2337, Carboplatin, Cisplatin, 5-fluorouracil, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
53
States / cities
Little Rock, Arkansas • Beverly Hills, California • Escondido, California + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 29, 2026, 3:35 PM EDT
Completed No phase listed Observational

Brain Imaging of Tinnitus

NCT00359931
View directory record Official record
Conditions
Hearing Disorder
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
30 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma

NCT02383498
View directory record Official record
Conditions
Chordoma
Interventions
Placebo, GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
Other · Biological · Radiation + 1 more
Lead sponsor
NantCell, Inc.
Industry
Eligibility
18 Years to 100 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 1 Interventional

Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors

NCT01445509
View directory record Official record
Conditions
Solid Tumors
Interventions
Bevacizumab, Dasatinib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Terminated Phase 2 Interventional

Evaluation of the Safety and Efficacy of Ang-(1-7) to Enhance Cognitive Function in Participants Undergoing CABG

NCT03252093
View directory record Official record
Conditions
Coronary Artery Bypass Surgery, Cognitive Impairment
Interventions
Angiotensin-(1-7), Placebo for Angiotensin-(1-7)
Drug
Lead sponsor
University of Arizona
Other
Eligibility
60 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
5
States / cities
Phoenix, Arizona • Tucson, Arizona • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 29, 2026, 3:35 PM EDT
Completed No phase listed Observational

Study of Etoposide in Breast Cancer Patients

NCT00026949
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Female only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 3 Interventional

Oral Care to Reduce Mouth and Throat Infections in Critically Ill Patients

NCT00078663
View directory record Official record
Conditions
Critical Illness
Interventions
Oral Care
Behavioral
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland • Fairfax, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 3:35 PM EDT
Terminated Phase 3 Interventional

A Ten-Week Study Evaluating The Effectiveness And Safety Of Zoloft In Children And Adolescents With A Diagnosis Of PTSD

NCT00150306
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Zoloft (Sertraline)
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
23
States / cities
Scottsdale, Arizona • Sacramento, California • San Diego, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Oct 29, 2026, 3:35 PM EDT
Completed No phase listed Observational

A Pilot Study of a Protein Profile Test in Ovarian Cancer Patients in Remission to See if Protein Changes Can Predict Relapse (be Predictive of Cancer Relapse)

NCT00001938
View directory record Official record
Conditions
Ovarian Neoplasm
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 100 Years · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Oct 29, 2026, 3:35 PM EDT
Terminated Not applicable Interventional Results available

2-5 Intermittent Caloric Restriction in HIV

NCT03489109
View directory record Official record
Conditions
Human Immunodeficiency Virus, Metabolic Syndrome
Interventions
Intermittent fasting, Standard of Care
Behavioral · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 29, 2026, 3:35 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Noradrenergic Transmission in the Brain

NCT07686393
View directory record Official record
Conditions
Healthy
Interventions
11C-ARMI
Drug
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years to 105 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon

NCT03600714
View directory record Official record
Conditions
Liver Disease, Hepatitis D
Interventions
Peg-interferon lambda, Lonafarnib, Ritonavir
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 1 Interventional Results available

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

NCT01772004
View directory record Official record
Conditions
Solid Tumors
Interventions
Avelumab
Drug
Lead sponsor
EMD Serono Research & Development Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,756 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
53
States / cities
Goodyear, Arizona • Scottsdale, Arizona • Rogers, Arkansas + 45 more
Source: ClinicalTrials.gov public record
Updated Dec 20, 2021 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Viral Kinetics, Interferon Stimulated Genes (ISGs) and mirRNA Among Subjects Infected With Different Hepatitis C Virus Genotypes During Therapy With Sofosbuvir and GS-5816

NCT02468648
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
Sofosbuvir, GS-5816
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy (Effect on Disease) and Safety of Finerenone in Participants With Heart Failure and Left Ventricular Ejection Fraction (Proportion of Blood Expelled Per Heart Stroke) Greater or Equal to 40%

NCT04435626
View directory record Official record
Conditions
Heart Failure
Interventions
Finerenone (BAY94-8862), Placebo
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
40 Years and older
Enrollment
6,016 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
107
States / cities
Birmingham, Alabama • Fairhope, Alabama • Mobile, Alabama + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Oct 29, 2026, 3:35 PM EDT